Pharma & Biotech VC & Investment News
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Today's issue
Refine Search
Biotechnology
Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, has closed its initial public offering, raising approximately $362 million. 17 September 2024
Biotechnology
American mRNA-immunotherapy start-up Myeloid Therapeutics has launched a subsidiary, Aurora Biosynthetics, in Australia. 16 September 2024
Biotechnology
San Diego-based Vironexis Biotherapeutics, a company developing AAV-delivered T-cell immunotherapies, has emerged from stealth mode. 16 September 2024
Pharmaceutical
Germany’s Pentixapharm is planning a public offering of new shares as part of its spin-off from Eckert & Ziegler, a leading specialist in radioisotopes for medical, scientific and industrial applications. 12 September 2024
Pharmaceutical
Bain Capital Life Sciences has announced the closing of its fourth fund, securing approximately $3 billion in total commitments. 12 September 2024
Pharmaceutical
EQT Life Sciences revealed that it has led a 93 million-euro ($102.5 million) oversubscribed Series A fundraise in PanTera, a Belgian radioisotope producer. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
Terns Pharmaceuticals, a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering. 11 September 2024
Pharmaceutical
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Pharmaceutical
Superluminal Medicines, a US firm using generative biology, chemistry and machine learning in an attempt to revolutionize the speed and accuracy of how medicines are created, has closed a $120 million Series A funding round. 10 September 2024
Biotechnology
Epsilogen, a specialist in the development of immunoglobulin E (IgE) antibodies to treat cancer, has announced the completion of a £12.5 million ($16.4 million) Series B expansion financing. 9 September 2024
Biotechnology
MBX Biosciences, a US biopharma focused on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders, has announced the launch of its initial public offering (IPO). 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Biotechnology
Acepodia has entered a strategic clinical collaboration with Pfizer Ignite to accelerate the development of its Antibody-Cell Conjugation (ACC) platform in autoimmune diseases. 4 September 2024
Biotechnology
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Pharmaceutical
Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024
Biotechnology
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Biotechnology
Chinese biotech DualityBio has shown that it means business in a filing to the Hong Kong stock exchange that reveals its plans for an initial public offering (IPO). 28 August 2024
Biotechnology
Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, has closed its initial public offering, raising approximately $362 million. 17 September 2024
Biotechnology
American mRNA-immunotherapy start-up Myeloid Therapeutics has launched a subsidiary, Aurora Biosynthetics, in Australia. 16 September 2024
Biotechnology
San Diego-based Vironexis Biotherapeutics, a company developing AAV-delivered T-cell immunotherapies, has emerged from stealth mode. 16 September 2024
Pharmaceutical
Germany’s Pentixapharm is planning a public offering of new shares as part of its spin-off from Eckert & Ziegler, a leading specialist in radioisotopes for medical, scientific and industrial applications. 12 September 2024
Pharmaceutical
Bain Capital Life Sciences has announced the closing of its fourth fund, securing approximately $3 billion in total commitments. 12 September 2024
Pharmaceutical
EQT Life Sciences revealed that it has led a 93 million-euro ($102.5 million) oversubscribed Series A fundraise in PanTera, a Belgian radioisotope producer. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
Terns Pharmaceuticals, a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering. 11 September 2024
Pharmaceutical
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Pharmaceutical
Superluminal Medicines, a US firm using generative biology, chemistry and machine learning in an attempt to revolutionize the speed and accuracy of how medicines are created, has closed a $120 million Series A funding round. 10 September 2024
Biotechnology
Epsilogen, a specialist in the development of immunoglobulin E (IgE) antibodies to treat cancer, has announced the completion of a £12.5 million ($16.4 million) Series B expansion financing. 9 September 2024
Biotechnology
MBX Biosciences, a US biopharma focused on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders, has announced the launch of its initial public offering (IPO). 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Biotechnology
Acepodia has entered a strategic clinical collaboration with Pfizer Ignite to accelerate the development of its Antibody-Cell Conjugation (ACC) platform in autoimmune diseases. 4 September 2024
Biotechnology
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Pharmaceutical
Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024
Biotechnology
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Biotechnology
Chinese biotech DualityBio has shown that it means business in a filing to the Hong Kong stock exchange that reveals its plans for an initial public offering (IPO). 28 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze